Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis.
Andres Cordova SanchezFarzam KhokharDanielle A OlonoffRobert L CarhartPublished in: Cardiovascular drugs and therapy (2022)
In conclusion, HCQ was slightly beneficial in decreasing MACE and cerebral infarction in patients with RA. These associations were significantly lower in patients taking methotrexate or biologics. Although there was a significant decrease in the risk of AMI in all patients with RA, these results were not replicated in subgroup analyses, and there was an apparent increased risk of AMI with the use of HCQ in patients using biologics.
Keyphrases
- end stage renal disease
- cardiovascular events
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis
- acute myocardial infarction
- cardiovascular disease
- prognostic factors
- type diabetes
- coronary artery disease
- heart failure
- randomized controlled trial
- magnetic resonance imaging
- patient reported outcomes
- magnetic resonance
- high dose
- systemic lupus erythematosus
- computed tomography
- percutaneous coronary intervention